An expert highlights how optimizing CAR T-cell therapy requires simplifying the treatment process, reducing insurance delays, addressing that 40% to 50% of patients may need further therapy, managing ...

An expert discusses that while CAR T-cell therapies carry risks such as cytokine release syndrome and neurotoxicity, advancements in supportive care and monitoring have significantly improved their ...